Introduction
There have been only two reports of acute graft vs host disease (aGVHD) in kidney graft recipients, and these were apparently due to blood transfusions [1, 2] . We report the first case of donor-derived aGVHD occurring in a kidney transplant patient who received a graft from a '0 HLA mismatched' donor. aGVHD is more often reported in intestinal or liver transplant recipients. The diagnosis is often delayed because the early signs are attributed to drug reactions or infections. These include skin rash, fever, diarrhoea and/or liver dysfunction. Later the patients develop pancytopenia, pre-disposing them to infection and bleeding, which are the most frequent causes of death [3] . The transplanted organ is noticeably spared since it is of donor origin. Mortality is very high, particularly once the patient becomes pancytopenic. The diagnosis is confirmed by demonstrating large numbers of donor lymphocytes in the patient's circulation.
Close matching of HLA antigens between the donor and the recipient is the strongest risk factor for aGVHD in liver transplant recipients. However, such close HLA matches are very common in kidney transplant recipients because these '0 HLA antigen mismatched' transplants are given high priority. We present this case in order to raise awareness that aGVHD can occur after kidney transplantation.
Case report
The patient was a 20-year-old Caucasian woman who had end-stage renal disease due to systemic lupus erythematosis. Her donor was an 18-year-old Hispanic male who was homozygous for HLA A2, B13, DR7(0701) and DQ2(0201). The patient's HLA type was HLA A2, 3, B13, 35, DR2(1501), 7(0701), DQ6(0602), DQ2(0201). She did not receive any blood products during surgery. Immunosuppression included cyclosporin, azathioprine and prednisone. She developed cyclosporin toxicity and her dose was decreased. She also developed a disruption of the ureteroneocystostomy, which was repaired. Otherwise, her post-operative recovery was uneventful and she was discharged on the seventh post-operative day (POD).
On the 61st POD, she developed a fever of unknown origin, neutropenia and elevated liver function tests. Her azathioprine and birth control pills were discontinued and she was given two doses of GM-CSF. Her symptoms resolved and she was discharged the next day. She presented again with fever and neutropenia on the 78th POD. Multiple blood cultures were negative. Urine viral cultures grew cytomegalovirus and adenovirus, so she was started on gancyclovir and her symptoms improved significantly. Her leucopenia was treated with GM-CSF and her leucocyte count peaked at 22 Â 10 9 /l, then fell to 2 Â 10 9 /l within 2 days of discontinuing GM-CSF. Her platelet count also dropped to 41 Â 10 9 /l. GM-CSF was restarted and her leucocyte count again rose to 26 Â 10 9 /l. She was also noted to have oropharyngeal thrush. She developed a fever to 1048C on the 88th POD and blood cultures grew a methacillin-resistant staphylococcus. Her intravenous catheter was pulled and a new subclavian catheter placed. She was treated initially with nafcillin, which was subsequently changed to vancomycin. Her gancyclovir dosage was stopped. She was readmitted on the 99th POD because she had developed itching and a diffuse skin rash, 4 days after starting vancomycin. She continued to have fevers up to 1038C. Repeated blood and urine cultures were Correspondence and offprint requests to: Douglas M. Smith, MD, PhD, Transplant Immunology Laboratory, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA. Email: dsmith@baylorhealth.edu negative. Her antibiotics were stopped and the rash eventually faded. Viral titres for CMV showed a seroconversion with marked rise in IgG to CMV. She had guiac-positive stools and was anaemic. Endoscopy revealed diffuse gastritis and duodenitis, and biopsies were consistent with CMV infection. She was started on oral gancyclovir. She was discharged to the rehabilitation unit on the 111th POD.
The patient was readmitted for the final time on the 123rd POD, with fever and a generalized desquamating rash. Gancyclovir was restarted and blood cultures drawn. Her blood cultures subsequently grew methacillin-resistant staphylococci and she was treated with trimethiprim-sulfa. She developed right-sided pleuritic chest pain and a right upper lobe infiltrate. Her antibiotic was changed to ceferoxime (zinacef), and her pneumonia and septicaemia resolved over the next 2 weeks. Her gancyclovir was discontinued on the 137th POD. She developed nausea and vomiting on the 143rd POD. Endoscopy showed gastritis and duodenitis, which was biopsied and was consistent with CMV infection. She was treated with gancyclovir and cytogam.
On the 145th POD, her skin rash persisted, she was noted to have pain in her palms and soles of her feet, and her neutrophil count dropped to 1.2 Â 10 9 /l. A diagnosis of aGVHD was considered. Repeat HLA class I typing by serology showed only the donor's HLA type. HLA class II typing by PCR-SSP was performed on DNA isolated from unfractionated leucocytes and showed both of the recipient's haplotypes. The patient's differential blood count at that time contained only 28% lymphocytes.
The patient was treated by increasing her steroid dose and GM-CSF. Within 3 days, her neutrophil count rose to a peak of 13 Â 10 9 /l, then GM-CSF was discontinued and her neutrophil count stabilized at about 3.4 Â 10 9 /l. Her symptoms improved and she was relatively stable for the next 3 weeks. Between the 174th and 176th POD, her erythroderma became worse and she began to slough skin from her palms. She became progressively more pancytopenic, despite restarting GM-CSF. Her gancyclovir was stopped and her immunosuppression was changed from ciclosporin to FK-506. She became febrile and developed a right upper lobe pulmonary infiltrate on the 190th POD.
Results of variable number tandem repeat (VNTR) typing collected on the 170th day showed only the recipient's phenotype; however, lymphocytes represented only 4% of the blood leucocytes at that time. Chromosomal analysis using fluorescent in situ hybridization (FISH) on a specimen collected on the 199th POD showed that all of the myeloid cells were XX (recipient) and all of the lymphocytes were XY (donor). Repeat serological typing of HLA antigens again showed only the donor's HLA type.
The consensus was then that the underlying disease process was aGVHD and that the patient's prognosis was grave. The patient's neutrophil continued to drop to less than 0.1 Â 10 9 /l, and it was decided to attempt a stem cell transplant from her father who was mismatched for only one HLA-B antigen. On the eighth post-transplant, day she developed an elevated left hemidiaphragm and opacification of the left chest. Bronchoscopy was performed, which revealed a left mucous plug. The plug was removed and a bronchoalveolar lavage was performed. An examination of the material revealed numerous septate hyphae consistent with aspergillus. The patient required ventilatory support. She died on the 12th day post-bone marrow infusion and 225th POD.
Major findings at autopsy included fungal bronchopneumonia and pericarditis. Cultures grew Aspergillus fumigatus and Candida albicans. Viral cultures also grew adenovirus. The bone marrow was markedly hypocellular, but did have some evidence of myelopoiesis.
Discussion
GVHD occurs when three conditions are met: (i) the graft contains a sufficient number of immunologically competent cells; (ii) the host possesses important transplantation antigens that are lacking in the graft so that the host seems foreign to the grafted cells; and (iii) the host is not able to mount a sufficient immunological response against the grafted cells [4] .
The dose of graft lymphocytes is important in determining the risk of aGVHD associated with solid organ transplants. The greatest risk occurs in intestinal and liver transplants [3, 5, 6] . The liver contains about 1.8 Â 10 10 passenger lymphocytes [7] . Pretreatment of small bowel grafts by irradiation is effective in reducing the incidence of aGVHD in intestinal transplants [6] . Simultaneous infusion of donor bone marrow, in order to induce donor chimerism, has been associated with an increased incidence of aGVHD [8] , and universal leucocyte depletion of blood transfusions has led to a decrease in transfusion-associated aGVHD [9] .
The ability of the host to mount an effective immune response to the donor lymphocytes may be affected by close HLA matching of the donor. This is the most important risk factor for the development of aGVHD following liver transplantation or blood transfusion in non-immunocompromised patients [3, 10, 11] . In closely matched liver transplants, the risk of aGVHD can be as high as 20%. Transfusion-associated aGVHD occurs frequently when there is a one-way HLA match [12] . In our case, there was a one-way HLA match, which undoubtedly played a role in reducing the recipient's response to the donor T-cells. However, the use of '0 HLA antigen mismatched' donors is common in renal transplantation, since they are given a high priority.
Experiments in mice have shown that NK cells play an important role in determining whether bone Graft vs host disease following kidney transplantation 2657 marrow transplants from one-way MHC-matched donors develop aGVHD [13] . This depends on killer immunoglobulin-like receptors on the NK cells that may kill donor cells that lack HLA class I antigens that are present in the host (missing self) [14] . Experiments in rats have shown that the induction of donor-specific tolerance by creating mixed haematopoietic chimeras predisposed the animals to aGVHD when challenged with donor lymphocytes or grafts [15, 16] . Kaneda et al. [17] performed lung transplants in rats that had been made tolerant by inducing mixed chimerism and found that the animals developed aGVHD unless the lung graft was irradiated. This risk needs to be kept in mind when designing clinical tolerance induction protocols.
The diagnosis of aGVHD was delayed in this case for several reasons. First, aGVHD has not been described before in an untransfused kidney transplant recipient. Second, the patient's signs and symptoms could be explained by her CMV infection, Staphylococcal septicemia and possible drug reactions. However, once the diagnosis was suspected, it was clearly confirmed by repeat HLA serological typing and karyotyping, which also confirmed that the origin of the lymphocytes was the kidney donor.
In our patient, we can say that more than 90% of the circulating T-lymphocytes were of donor origin. Serological HLA typing can detect a mixture of cells with differing HLA types as long as the minor cell population is greater than 10%, and none of the HLA types that were unique to the patient are detectable in our patient. Serological typing was performed on purified T-cells that were selected by adherence to anti-CD8-coated magnetic beads. This was also supported by the FISH analysis that showed only the donor's XY genotype in lymphocytes. The typing of HLA class II antigens by PCR-SSP and the VNTR testing were misleading because they were performed on DNA isolated from unfractionated leucocytes that were mostly myeloid cells. In most cases, the myeloid cells remain of recipient type, which was also documented in the FISH analysis. DNA-based testing can be very useful in documenting and quantifying lymphocyte chimerism but it must always be performed on fractionated cell populations.
There is no uniformly effective treatment for aGVHD associated with solid organ transplantation. In most cases, patients have been treated by increasing immunosuppression and haematopoietic cytokines to support bone marrow function. However, this nearly always results in only temporary improvement, as was true in this case. The patient's symptoms became temporarily better when her steroids were increased and she was given GM-CSF, but she had a protracted course of recurring infections and neutropenia, which ultimately led to her death from fungal and viral infections. We have recently had some success with dramatic reduction in immunosuppression. This may be particularly effective in cases where the onset is late and the course is protracted. Several attempts have been made to treat the patient with an allogeneic bone marrow transplant, but patients have generally been too ill by the time a donor could be found and have died despite these attempts, as was the case in our patient.
In summary, we have reported the first case of aGVHD in a kidney transplant recipient due to engraftment of donor lymphocytes. The one-way HLA match of the donor was undoubtedly a contributing risk factor but since many similarly matched transplants have been performed without aGVHD, there must be additional unknown contributing factors. A high index of suspicion is needed to make the diagnosis early and the best method to confirm the diagnosis is to confirm high levels of donor lymphocyte chimerism using HLA typing or DNA testing for engraftment using DNA isolated from T-lymphocytes. The clinical course of solid organ transplant-associated aGVHD is very often fatal and more research is needed to develop effective methods for treatment or prevention.
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